Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 148

Sort by

Sort Order Select

Journal Articles

Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma

Amin Sobh, PhD, Charlotte Kaestner, Alberto Riva, PhD, Jonathan D. Licht, MD

Blood (2019) 134 (Supplement_1): 3757.

https://doi.org/10.1182/blood-2019-125951

Published: 2019

Journal Articles

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Zhihong Zeng, Natalia Baran, PhDMD, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, MSc, Philip Lorenzi, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Courtney D. DiNardo, MDMSc, Joshua Murtie, Danielle Ulanet, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3911.

https://doi.org/10.1182/blood-2019-125469

Published: 2019

Journal Articles

Targeting the Plasma Cell Specific Purine Metabolic Enzyme, AMPD1, Induces Multiple Myeloma Cell Death Accompanying NAD Depletion

Yawara Kawano, MD PhD, Takayuki Sasano, Saki Kushima, Yuki Inada, Nao Nishimura, MD, Hiroyuki Hata, MD PhD, Masao Matsuoka, MD PhD

Blood (2019) 134 (Supplement_1): 3097.

https://doi.org/10.1182/blood-2019-125756

Published: 2019

Journal Articles

Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded Cohort

Blood (2019) 134 (Supplement_1): 3345.

https://doi.org/10.1182/blood-2019-123432

Published: 2019

Journal Articles

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Takuji Yamauchi, MD PhD, Kohta Miyawaki, MD, Yuichiro Semba, MD PhD, Fumihiko Nakao, MD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Simon Osborne, PhD, Luca Pinello, PhD, Deborah Taylor, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 1390.

https://doi.org/10.1182/blood-2019-127047

Published: 2019

Journal Articles

Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells

Arghya Ray, PhD, Leutz Buon, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 510.

https://doi.org/10.1182/blood-2019-123333

Published: 2019

Journal Articles

Heme Overload Triggers Xanthine Oxidase Release and Mediates the Inflammatory Response

Heidi M Schmidt, BSE, Eric Kelley, PhD, Adam Straub, PhD

Blood (2019) 134 (Supplement_1): 3529.

https://doi.org/10.1182/blood-2019-130274

Published: 2019

Journal Articles

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

Kohta Miyawaki, MD PhD, Takuji Yamauchi, MD PhD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Hiroaki Miyoshi, MD PhD, Simon Osborne, PhD, Deborah Taylor, PhD, Koichi Ohshima, MD PhD, Koji Kato, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 396.

https://doi.org/10.1182/blood-2019-129613

Published: 2019

Journal Articles

Methotrexate-Loaded Biodegradable Polymeric Micelles for Lymphoma Therapy in Mouse Model

Mengyao Wang, MD, Ying Qu, PhD, Zhiyong Qian, PhD, Ting Niu, MD PhD

Blood (2018) 132 (Supplement 1): 4181.

https://doi.org/10.1182/blood-2018-99-119151

Published: 2018

Journal Articles

Differential Genome-Wide Mutational Patterns in Indolent B-Cell Lymphomas

Julieta Haydee Sepulveda Yanez, MSc, Diego Alvarez, MSc, Jose Fernandez-Goycoolea, Cornelis A.M. van Bergen, PhD, Hendrik Veelken, MD PhD, Marcelo A. Navarrete, PhD

Blood (2018) 132 (Supplement 1): 4102.

https://doi.org/10.1182/blood-2018-99-116174

Published: 2018

Journal Articles

Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Single-Institution Analysis

Daniel Alan Kerr, MD PhD, Kristen Gonter-Aubin, DO, Ashley Rose, MD, Thanh Lana Nguyen, Javier Pinilla Ibarz, MD, Julio C. Chavez, MD

Blood (2018) 132 (Supplement 1): 5323.

https://doi.org/10.1182/blood-2018-99-118386

Published: 2018

Journal Articles

Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells

Arghya Ray, PhD, Leutz Buon, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 244.

https://doi.org/10.1182/blood-2018-99-117887

Published: 2018

Journal Articles

Novel Evidence That the Ectonucleotidases CD39 and CD73, Which Are Expressed on Hematopoietic Stem/Progenitor Cells (HSPCs), Regulate Mobilization and Homing - Studies in CD39-/- and CD73-/- Mice and with Small-Molecule CD39 and CD73 Inhibitors

Mateusz Adamiak, PhD, Kamila Bujko, MS, Anna Lenkiewicz, PhD, Magdalena Kucia, PhD DSci, Janina Ratajczak, MD PhD DSci, Mariusz Z Ratajczak, MD PhD DSci

Blood (2018) 132 (Supplement 1): 2060.

https://doi.org/10.1182/blood-2018-99-110631

Published: 2018

Journal Articles

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Michele Merli, MD, Stefano Luminari, MD, Lucia Farina, Federica Cocito, MD, Irene Defrancesco, MD, Guido Gini, MD, Annalisa Arcari, MD, Greta Scapinello, MD, Massimo Gentile, MD, Maria Goldaniga, MD, Giacomo Loseto, MD, Emanuele Cencini, MD, Antonino Greco, MD, Andrea Ferrario, MD, Benedetta Bianchi, MD, Francesca Gaia Rossi, MD, Silvia Bolis, MD, Francesco Passamonti, MD, Luca Arcaini, MD

Blood (2018) 132 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2018-99-113536

Published: 2018

Journal Articles

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies

Ian W. Flinn, MD PhD, Marco Montillo, MD, Zsolt Nagy, MD PhD, Zoltán Gasztonyi, MD, Matthew S. Davids, MD, Klaus Geissler, MD, Jose J. Rifon Roca, MD, Leanne Berkhan, ADHB, Fritz Offner, MD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, Julio Delgado, MD

Blood (2018) 132 (Supplement 1): 3146.

https://doi.org/10.1182/blood-2018-99-120027

Published: 2018

Journal Articles

Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma

Yixin Yao, PhD, Yang Liu, PhD, Hui Guo, PhD, Makhdum Ahmed, MD PhD MPH, Shabnam Bhuiyan, MSc, Krystle Nomie, PhD, Liang Zhang, MD PhD, Michael Wang, MD

Blood (2018) 132 (Supplement 1): 2945.

https://doi.org/10.1182/blood-2018-99-112192

Published: 2018

Journal Articles

The Purine Metabolic Enzyme AMPD1 Is a Novel Therapeutic Target for Multiple Myeloma

Yawara Kawano, MD PhD, Yuki Inada, Takayuki Sasano, Nao Nishimura, MD, Hiroyuki Hata, MD PhD, Masao Matsuoka, MD PhD

Blood (2018) 132 (Supplement 1): 5614.

https://doi.org/10.1182/blood-2018-99-118603

Published: 2018

Journal Articles

Proteometabolomics of Melphalan Resistance in Multiple Myeloma

David C. Koomen, BS, Joy D. Guingab, PhD, Paula S. Oliveira, Bin Fang, PhD, Min Liu, PhD, Eric A. Welsh, PhD, Mark B. Meads, PhD, Tuan Nguyen, Laurel E. Meke, Steven A. Eschrich, PhD, Timothy J. Garrett, PhD, John M. Koomen, PhD, Kenneth H. Shain, MD PhD

Blood (2018) 132 (Supplement 1): 5619.

https://doi.org/10.1182/blood-2018-99-117747

Published: 2018

Journal Articles

Leflunomide Inhibits c-Myc Signaling and Impairs Myeloma Cell Growth

Ralf Buettner, PhD, Corey James Morales, BA, BS, Enrico Caserta, PhD, Domenico Viola, BS, Joycelynne M. Palmer, PhD, Xiwei Wu, PhD, Nagarajan Vaidehi, PhD, Hongzhi Li, PhD, Tim Synold, PhD, Amrita Krishnan, MD, Flavia Pichiorri, PhD, Michael Rosenzweig, MD, Steven T. Rosen, MD

Blood (2017) 130 (Supplement 1): 4426.

https://doi.org/10.1182/blood.V130.Suppl_1.4426.4426

Published: 2017

Journal Articles

HEME Degradation Enzyme Biliverdin IXb Reductase Is Required for Stem Cell Glutamine Metabolism

Zongdong Li, PhD, Wadie F. Bahou, MD

Blood (2017) 130 (Supplement 1): 3763.

https://doi.org/10.1182/blood.V130.Suppl_1.3763.3763

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Targeting the Plasma Cell Specific Purine Metabolic Enzyme, AMPD1, Induces Multiple Myeloma Cell Death Accompanying NAD Depletion

Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded Cohort

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells

Heme Overload Triggers Xanthine Oxidase Release and Mediates the Inflammatory Response

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

Methotrexate-Loaded Biodegradable Polymeric Micelles for Lymphoma Therapy in Mouse Model

Differential Genome-Wide Mutational Patterns in Indolent B-Cell Lymphomas

Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Single-Institution Analysis

Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells

Novel Evidence That the Ectonucleotidases CD39 and CD73, Which Are Expressed on Hematopoietic Stem/Progenitor Cells (HSPCs), Regulate Mobilization and Homing - Studies in CD39-/- and CD73-/- Mice and with Small-Molecule CD39 and CD73 Inhibitors

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies

Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma

The Purine Metabolic Enzyme AMPD1 Is a Novel Therapeutic Target for Multiple Myeloma

Proteometabolomics of Melphalan Resistance in Multiple Myeloma

Leflunomide Inhibits c-Myc Signaling and Impairs Myeloma Cell Growth

HEME Degradation Enzyme Biliverdin IXb Reductase Is Required for Stem Cell Glutamine Metabolism

Email alerts

ASH Publications

American Society of Hematology